U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06973720) titled 'A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight' on May 06.
Brief Summary: This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo. Participants are eligible if they have overweight or obesity and do not have type 2 diabetes.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight or Obesity
Intervention:
DRUG: MET097
For subcutaneous administration.
DRUG: Placebo
Sterile 0.9% (w/v) saline for subcutaneous administration.
Recruitm...